PolyPeptide Group Reports 24% Growth in H1 2025

PolyPeptide Group AG announced a strong performance for the first half of 2025 with a 24% growth in revenue, reaching EUR 167.1 million. This increase was driven by a nearly doubling in metabolic therapeutics and a 37.9% rise in commercial revenue, largely due to expanded capabilities at its Belgian site.

The company reported improved EBITDA of EUR 4.4 million despite challenges like higher material costs and increased investments to support growth. Operating cash flow grew significantly, with net cash flow from operating activities at EUR 49.7 million versus EUR 0.5 million in H1 2024.

PolyPeptide revised its 2025 full-year guidance towards the upper end of expectations, anticipating continued growth driven by its expanded capacity and robust demand in the global peptide market. Strategic capital investments and new leadership appointments are set to bolster future expansion efforts.